ExSure
Mumbai, India· Est.
India’s first exosome‑based anti‑cancer drug‑delivery platform targeting cancer‑stem cells.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $400K
AI Company Overview
India’s first exosome‑based anti‑cancer drug‑delivery platform targeting cancer‑stem cells.
Oncology
Technology Platform
Exosome‑based targeted drug delivery platform (ExoDS) that isolates, loads, and engineers dendritic‑cell‑derived exosomes to selectively target cancer‑stem cells while sparing healthy tissue.
Opportunities
Rapidly growing global exosome therapeutics market and unmet need for affordable, targeted chemotherapy in India provide a clear path for commercialization and strategic partnerships.
Risk Factors
Regulatory uncertainty for exosome‑based drugs, scale‑up challenges for GMP‑grade exosome production, and competition from established nanocarrier companies could delay market entry.
Competitive Landscape
Key competitors include Codiak BioSciences, ExoThera, and other nanocarrier firms; ExSure differentiates through its focus on cancer‑stem‑cell targeting and a fully integrated reagent‑to‑therapy platform tailored for the Indian market.